Previous 10 | Next 10 |
- Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to Support the Development of GPS in Combination with a PD-1 Inhibitor in Ovarian Cancer - ...
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, ...
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, ...
SELLAS Life Sciences (NASDAQ: SLS ): Q2 GAAP EPS of -$0.13. More news on: SELLAS Life Sciences Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Multiple Clinical Milestones and Data Sets Expected by Year End / Q1 2020 - - Company to Host its First R&D Investor Day in Q4 2019 - NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “...
Nano cap SELLAS Life Sciences ( SLS +1.6% ) is up on average volume in reaction to the completion of enrollmen t in a Phase 2 clinical trial, VADIS , evaluating NeuVax (nelipepimut-S) (NPS), combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), in certain women with du...
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, ...
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung Cancers and Acute Myeloid Leukemia - - First Clinical Data Expected in First Qu...
Gainers: OMNOVA Solutions (NYSE: OMN ) +55% . SELLAS Life Sciences Group (NASDAQ: SLS ) +46% . Karyopharm Therapeutics (NASDAQ: KPTI ) +36% . One Stop Systems (NASDAQ: OSS ) +26% . NIO (NYSE: NIO ) +15% . Corvus Pharmaceuticals (NASDAQ: CRVS ) +15% . Melinta Therapeutics (NASDA...
SELLAS Life Sciences Group (NASDAQ: SLS ) has closed its public offering of 26,367,200 common shares and warrants to purchase same number of common shares and 73,632,800 pre-funded warrants. More news on: SELLAS Life Sciences Group, Inc., Healthcare stocks news, Stocks on the move, R...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...